Since coverage of Mayim Bialik's difficult GLP-1 experience ran on June 8, the conversation around these drugs' side effects has only gotten louder — and now there's a new drug being pitched as the solution to one of the most common complaints.

What the Research Actually Says

Apitegromab is a myostatin inhibitor — it blocks a protein that naturally limits muscle growth. The theory is straightforward: if GLP-1 drugs cause you to lose muscle alongside fat, block the signal that allows muscle to shrink.

A trial of 102 adults, mostly women, was published in Nature Medicine. Participants who took apitegromab alongside their GLP-1 medication maintained more muscle mass while still losing fat, compared to those who didn't take it. That's according to body scan data reported by BBC News.

102 People Is NOT a Large Trial

One hundred and two participants — mostly women — is a small study. It's hypothesis-generating, not proof this drug works safely at scale.

The researchers themselves acknowledged more evaluation is needed before anyone recommends it. That caveat is buried in paragraph four of most coverage. It should be paragraph one.

We've been down this road before. GLP-1 drugs themselves were celebrated as medical advances before the full side-effect profile emerged — muscle loss, nausea, severe gastrointestinal episodes, and the cosmetic problem being called "Ozempic butt." Now the pitch is: take the original drug, plus a second drug to fix what the first drug broke.

The 'Ozempic Butt' Problem Is Real

The underlying issue is legitimate. According to BBC News, around a third of weight loss from GLP-1 drugs like Wegovy and Mounjaro can come from muscle rather than fat. That is a significant and underreported problem.

Muscle is not like fat. You can't put it back on quickly. Once you lose it — especially if you're older — rebuilding it is hard, slow work. Muscle loss accelerates aging, increases fall risk, and degrades metabolic health.

US plastic surgeons are reporting a "noticeable uptick" in consultations related to body composition changes from GLP-1 use. That's cosmetic. The medical implications are more serious and less photogenic.

What Mainstream Coverage Is Missing

Left-leaning media coverage of this story is treating apitegromab as a breakthrough. That framing benefits pharmaceutical companies and does not serve patients.

Key questions are being sidelined:

Who funded the apitegromab trial? The source material doesn't say — and that matters enormously. Drug company-funded trials have a documented history of favorable outcomes that don't survive independent replication.

What are the side effects of apitegromab? Blocking myostatin sounds clean in theory. The body uses myostatin for reasons. A drug that suppresses it systemically could have consequences nobody has mapped yet in a population of 102 people.

Who profits from a second drug to fix the first drug? GLP-1 manufacturers — Novo Nordisk (Wegovy/Ozempic) and Eli Lilly (Mounjaro) — are already pulling in billions. If apitegromab gets approved as an add-on therapy, it creates a second revenue stream attached to the first. That's a business model, not just medicine.

The Common-Sense Take on GLP-1 Side Effects

Health authorities and prescribers have consistently told patients on GLP-1 drugs to eat enough protein and do strength training. That advice is free. It works. It doesn't require a second prescription.

The honest answer to "I'm losing muscle on Ozempic" for most people is: lift weights and eat protein. Not: take another novel drug.

Apitegromab might prove useful for specific populations. People with mobility limitations, sarcopenia risk, or other conditions may genuinely benefit from pharmacological muscle preservation. That's a real population worth studying.

But the rollout of this story — framed as a solution to a cosmetically embarrassing problem — undersells the real issue. "Ozempic butt" is a meme. Muscle loss in aging adults is a public health concern. Treating this as major news for the former obscures the seriousness of the latter.

The Bottom Line

Apitegromab is interesting. One hundred and two people is not enough. Nobody should be taking a second novel drug to fix a side effect of the first novel drug without substantially more data.

The researchers themselves said more studies are needed.

Patients deserve straight talk about both the promise and the limitations here. They're not getting it from coverage that leads with "Ozempic butt" in the headline.